Graham Capital Management L.P. Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Graham Capital Management L.P. has acquired a new position in Edwards Lifesciences Corporation, purchasing 14,933 shares valued at approximately $1.08 million.
• Edwards Lifesciences reported $0.67 EPS in its latest earnings, exceeding analyst expectations of $0.62 and showing an 11.9% revenue growth year-over-year.
• Multiple analysts have upgraded their ratings and target prices for Edwards Lifesciences, with an average target of $85.90 and a consensus rating of "Moderate Buy."

Graham Capital Management L.P. acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,933 shares of the medical research company's stock, valued at approximately $1,082,000.

A number of other institutional investors have also modified their holdings of EW. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $266,000. Bank Pictet & Cie Europe AG increased its position in Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after acquiring an additional 1,463 shares during the period. Aptus Capital Advisors LLC increased its holdings in Edwards Lifesciences by 25.8% in the 4th quarter. Aptus Capital Advisors LLC now owns 10,001 shares of the medical research company's stock valued at $740,000 after buying an additional 2,052 shares during the period. Benjamin Edwards Inc. lifted its position in Edwards Lifesciences by 25.1% during the 4th quarter. Benjamin Edwards Inc. now owns 19,168 shares of the medical research company's stock worth $1,419,000 after buying an additional 3,844 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in Edwards Lifesciences by 48.0% during the 4th quarter. Baird Financial Group Inc. now owns 177,392 shares of the medical research company's stock valued at $13,132,000 after purchasing an additional 57,522 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 1.2%

Shares of NYSE EW traded down $0.99 during midday trading on Monday, hitting $79.95. The company's stock had a trading volume of 1,784,158 shares, compared to its average volume of 4,442,391. The business's 50 day moving average is $78.77 and its two-hundred day moving average is $75.21. The firm has a market cap of $46.94 billion, a P/E ratio of 11.47, a price-to-earnings-growth ratio of 3.90 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 EPS. The firm's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock valued at $1,698,844 over the last 90 days. Insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EW. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Morgan Stanley lifted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.